Barclays’s Spero Therapeutics SPRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-204
| Closed | – | – | 4818 |
|
|
2022
Q2 | $0 | Sell |
204
-3,726
| -95% | – | ﹤0.01% | 4896 |
|
|
2022
Q1 | $35K | Sell |
3,930
-25,441
| -87% | -$227K | ﹤0.01% | 4135 |
|
|
2021
Q4 | $470K | Buy |
29,371
+19,406
| +195% | +$311K | ﹤0.01% | 2557 |
|
|
2021
Q3 | $183K | Buy |
9,965
+4,401
| +79% | +$80.8K | ﹤0.01% | 3019 |
|
|
2021
Q2 | $77K | Sell |
5,564
-16,076
| -74% | -$222K | ﹤0.01% | 3227 |
|
|
2021
Q1 | $319K | Buy |
21,640
+14,940
| +223% | +$220K | ﹤0.01% | 2913 |
|
|
2020
Q4 | $130K | Sell |
6,700
-1,858
| -22% | -$36.1K | ﹤0.01% | 2885 |
|
|
2020
Q3 | $96K | Sell |
8,558
-1,151
| -12% | -$12.9K | ﹤0.01% | 3052 |
|
|
2020
Q2 | $130K | Buy |
9,709
+5,389
| +125% | +$72.2K | ﹤0.01% | 3010 |
|
|
2020
Q1 | $34K | Sell |
4,320
-7,041
| -62% | -$55.4K | ﹤0.01% | 3240 |
|
|
2019
Q4 | $109K | Buy |
11,361
+5,853
| +106% | +$56.2K | ﹤0.01% | 3428 |
|
|
2019
Q3 | $58K | Sell |
5,508
-1,281
| -19% | -$13.5K | ﹤0.01% | 3636 |
|
|
2019
Q2 | $78K | Buy |
6,789
+4,222
| +164% | +$48.5K | ﹤0.01% | 3696 |
|
|
2019
Q1 | $33K | Buy |
2,567
+2,131
| +489% | +$27.4K | ﹤0.01% | 3799 |
|
|
2018
Q4 | $2K | Sell |
436
-3,121
| -88% | -$14.3K | ﹤0.01% | 3943 |
|
|
2018
Q3 | $37K | Buy |
3,557
+3,069
| +629% | +$31.9K | ﹤0.01% | 3819 |
|
|
2018
Q2 | $7K | Sell |
488
-803
| -62% | -$11.5K | ﹤0.01% | 3967 |
|
|
2018
Q1 | $19K | Buy |
1,291
+335
| +35% | +$4.93K | ﹤0.01% | 3854 |
|
|
2017
Q4 | $11K | Buy |
+956
| New | +$11K | ﹤0.01% | 3816 |
|